Effect of Nafamostat on Postreperfusion Syndrome (PRS)
Primary Purpose
Liver Transplantation, Postreperfusion Syndrome
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Nafamostat
Normal saline
Sponsored by

About this trial
This is an interventional prevention trial for Liver Transplantation
Eligibility Criteria
Inclusion Criteria:
- >= 18 year old scheduled to undergo liver transplantation
Exclusion Criteria:
- Previous history of pulmonary, cardiovascular, or renal disease
- Previous history of allergic reactions to nafamostat
Sites / Locations
- Seoul National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
nafamostat
Control
Arm Description
The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
Outcomes
Primary Outcome Measures
Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS)
Before entering the study, we re-defined the criteria of PRS. From our clinical experiences, two types of PRS were observed according to its severity and treatment option. "Moderate" PRS was identical to previously defined PRS: more than 30% decrease of mean arterial pressure lasting over 1 min was observed within 5 min after reperfusion of the liver graft. However, we differentiated a "severe" form of PRS, in which MAP rapidly fell below 40 mmHg, from the moderate one, because severe PRS required prompt intervention to prevent a permanent damage of vital organs.
Secondary Outcome Measures
Full Information
NCT ID
NCT01001403
First Posted
October 23, 2009
Last Updated
May 4, 2010
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01001403
Brief Title
Effect of Nafamostat on Postreperfusion Syndrome (PRS)
Official Title
Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft
Study Type
Interventional
2. Study Status
Record Verification Date
May 2010
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
April 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Seoul National University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Transplantation, Postreperfusion Syndrome
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
nafamostat
Arm Type
Experimental
Arm Description
The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
Intervention Type
Drug
Intervention Name(s)
Nafamostat
Intervention Description
0.2 mg/kg as bolus 1 minute before reperfusion
Intervention Type
Drug
Intervention Name(s)
Normal saline
Intervention Description
10 ml of normal saline
Primary Outcome Measure Information:
Title
Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS)
Description
Before entering the study, we re-defined the criteria of PRS. From our clinical experiences, two types of PRS were observed according to its severity and treatment option. "Moderate" PRS was identical to previously defined PRS: more than 30% decrease of mean arterial pressure lasting over 1 min was observed within 5 min after reperfusion of the liver graft. However, we differentiated a "severe" form of PRS, in which MAP rapidly fell below 40 mmHg, from the moderate one, because severe PRS required prompt intervention to prevent a permanent damage of vital organs.
Time Frame
during 5 min after reperfusion of liver graft
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
>= 18 year old scheduled to undergo liver transplantation
Exclusion Criteria:
Previous history of pulmonary, cardiovascular, or renal disease
Previous history of allergic reactions to nafamostat
Facility Information:
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Effect of Nafamostat on Postreperfusion Syndrome (PRS)
We'll reach out to this number within 24 hrs